Capricor Therapeutics, Inc.
Capricor Therapeutics is a clinical-stage regenerative medicine company with minimal government dependence and no measurable political engagement.
BusinessWhat CAPR does
Capricor develops exosome-based therapeutics for cardiovascular and other diseases, primarily through clinical trials and research partnerships. Revenue is minimal as the company is pre-commercial, relying on capital raises and grant funding rather than product sales or government contracts.
12 months past · 3 months futureCAPR activity timeline
Lifetime Government AwardsCAPR federal contracts
CAPR doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding CAPR
Congressional TradesWho in Congress is trading CAPR
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting CAPRLive legislation impacting this stock
Political ProfileWhere CAPR sits in Washington
As a pre-commercial biotech with no lobbying activity, politician trades, or legislative naming, the stock is driven by clinical trial outcomes and capital markets rather than political events.
Regulatory ExposureThreats & opportunities
Regulatory threats
- FDA clinical trial requirements
- manufacturing compliance
Regulatory opportunities
- Regenerative medicine advanced therapy (RMAT) designation
- NIH grant funding expansion
Live signals + predictions for CAPR — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades CAPR
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord